1. Oette M, Kaiser R, Daumer M, et al. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 2004; 9:273-278.
  2. Babic DZ, Zelnikar M, Seme K, et al. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res 2006; 118:156-163.
  3. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 2006; 11:575-579.
  4. Oette M, Kaiser R, Daumer M, et al. Epidemiologie der primären Medikamentenresistenz bei chronisch HIV-Infizierten in Nordrhein-Westfalen 2001-2005. Dtsch Med Wochenschr 2007; 132:977-982.
  5. Bennett D, McCormick L, Kline R, et al. U.S. surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 2005.
  6. Vercauteren J, Derdelinckx I, Deforche K, et al. Prospective collection of data on the prevalence of transmitted resistance in newly diagnosed HIV-infected individuals in Belgium in 2004. In: 3rd European HIV Drug Resistance Workshop. Athen, Griechenland, 2004.
  7. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
  8. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. Aids 2005; 19:487-494.
  9. de Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 2007; 23:879-885.
  10. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. Aids 2006; 20:223-231.
  11. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53:696-699.
  12. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
  13. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311-1316.
  14. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36:808-816.
  15. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6:592-599.
  16. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-163.
  17. Boyle B, Lackey P, Morales-Ramirez J, et al. Early assessment of adherence and treatment satisfaction differences in a qd versus a bid or more frequently dosed HAART regimen. Int J Infect Dis 2004; 8 (Suppl 1):S36.
  18. Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) study. Int J STD AIDS 2003; 14 Suppl 1:34-36.
  19. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. Aids 2001; 15:1369-1377.
  20. Mildvan D, Tierney C, Gross R, et al. Randomized comparison in treatment-naïve patients of once-daily vs twice-daily lopinavir/ritonavir-based ART and comparison of once-daily self-administered vs directly observed therapy. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 2007.
  21. Johnson MA, Gathe JC, Jr., Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43:153-160.
  22. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection - ACTG 5142. In: 16th International AIDS Conference. Toronto, Canada, 2006.
  23. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11:1170-1172.
  24. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 2007.
  25. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients Infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 2007.
  26. Langmann P, Zilly M, Weissbrich B, et al. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir. Eur J Med Res 2000; 5:59-62.
  27. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
  28. Taylor S, Allen S, Fidler S, et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for two weeks or longer. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 2004.
  29. Deutsche AIDS-Gesellschaft (DAIG) und Österreichische AIDS-Gesellschaft (ÖAG) in Abstimmung mit weiteren Fachgesellschaften. Antiretrovirale Therapie der HIV-Infektion. 2005; besucht am 06.11.2007.
  30. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-449.
  31. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34:407-414.
  32. Schranz D, Brockmeyer NH, K. F, Petry R, Hower M. Improvements in self-reported gastrointestinal tolerability, Quality of Life (QoL) and therapy preference with lopinavir/ritonavir (LPV/r) after switching from BID soft-gel capsule (SGC) to BID tablets (TAB). In: 3. Deutsch-Österreichischer AIDS-Kongress Frankfurt a. Main, 2007.
  33. Schewe K, Fenske S, Schmeisser N, et al. Effect of switch from lopinavir soft gel capsules to lopinavir meltrex formulation on gastrointestinal side effects, quality of life, lipid, virologic and immunologic parameters. In: 3. Deutsch-Österreichischer AIDS-Kongress. Frankfurt a. Main, 2007.
  34. Raboud J, Lesosky M, Sterling S, Phillips E, Walmsley S, Bayoumi A. An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse drug events in an observational database. HIV Clin Trials 2007; 8:311-319.
  35. Kuhlmann B, Liess H. Leitlinien der DAGNÄ zur Unterstützung der Adhärenz im Rahmen einer antiretroviralen Therapie bei HIV-Infektion. 2004.

 Back to Top


Valid XHTML 1.0 Transitional